



JAGSONPAL PHARMACEUTICALS LIMITED

**Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015,
Haryana (India)**

**Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com
CIN NO. L74899DL1978PLC009181**

April 28, 2025

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block-G,
Bandra - Kurla Complex
Bandra (E), Mumbai-400051

Stock Code: JAGSNPHARM

Sub: Reply to the clarification sought by the Stock Exchange with reference to the significant increase in the volume of the security of the Company across Exchanges, in the recent past.

Ref. No.: NSE/CM/Surveillance/15392 dated April 25, 2025

Dear Sir/ Madam,

This is with reference to the captioned subject and your email seeking clarification from the Company regarding significant increase in the volume of the security of the Company across exchanges, in the recent past.

In response to the clarification sought, please note that all material information has been duly informed by the Company to the Stock Exchanges in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time. There is no other development/information required to be disclosed to stock exchanges in compliance of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to kindly take the same on record.

Thanking you,

For **Jagsonpal Pharmaceuticals Limited**

Pratham Rawal
Company Secretary & Compliance Officer